Product Information
VESICARE 10 MG TABLET is a brand product labeled by Astellas Pharma US, Inc., priced at $12.3099 per EA under NDC 51248015101. Its NADAC has been published 667 times since Nov 28, 2013.
FDA first approved this application on Nov 19, 2004.
The High Outlier badge above means this manufacturer's average price in the solifenacin succinate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
10 mg/1
Manufacturer
Astellas Pharma US, Inc.NDC
51248015101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
SOLIFENACIN SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA021518FDA Approved
11/19/2004
On Market Since
1/5/2005
Pharmacological Classes
Price Statistics
The NADAC for VESICARE 10 MG TABLET has been published 667 times since Nov 28, 2013, and over the history we have for it it has risen 88.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3099 per EA |
|---|---|
| All-time high | $12.5033 (Jul 13, 2022) |
| All-time low | $6.5416 (Nov 28, 2013) |
| 52-week high | $12.3125 |
| 52-week low | $12.2924 |
| Median price | $12.2607 |
| Average price | $11.0108 |
| Largest weekly change | +9.9% (Feb 25, 2015) |
| Weeks tracked | 667 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
+0.1%
6M
+0.1%
1Y
+0.1%
3Y
+1.2%
5Y
-1.5%
All
+88.2%
Last surveyed Sep 2, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
solifenacin succinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VESICARE 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VESICARE 10 MG TABLET, manufactured by Astellas Pharma US, Inc., is $12.3099 per EA (NDC 51248015101), effective Sep 2, 2026.
How has the price of VESICARE 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for VESICARE 10 MG TABLET has risen 88.2%. It has been tracked across 667 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VESICARE 10 MG TABLET?
Since Nov 28, 2013, the NADAC for VESICARE 10 MG TABLET has ranged from a low of $6.5416 (Nov 28, 2013) to a high of $12.5033 (Jul 13, 2022), with a median of $12.2607 per EA.
Are there cheaper alternatives to VESICARE 10 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SOLIFENACIN 10 MG TABLET, is $0.1617 per EA — about 99% below VESICARE 10 MG TABLET.
Who manufactures VESICARE 10 MG TABLET?
VESICARE 10 MG TABLET (NDC 51248015101) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.